Pishgahi Mahdi, Alirezaei Toktam, Hajimoradi Behzad, Nekooghadam S Mojtaba, Shahi Shima
Cardiology Department, Shohaday-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Internal Medicine Department, Shohaday-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Emerg (Tehran). 2018;6(1):e25. Epub 2018 Apr 22.
In massive pulmonary embolism (PE), fibrinolytic therapy is a potential lifesaving treatment; therefore, if other treatments are not available, the physicians encounter this question: can we accept the risk of complications from fibrinolytic therapy, especially intracranial hemorrhage, in the presence of absolute contraindication, in order to save the patient's life? Here, we describe three cases of massive PE with absolute contraindication for fibrinolytic therapy who presented to emergency department following dyspnea. Since, surgical or catheter embolectomy were not available and patients were very high risk for transferring to another hospital, systemic fibrinolytic was administered. The patients improved clinically and were discharged from hospital. It seems that, if no other acceptable treatments are available, physicians could consider fibrinolytic therapy, even at the presence of contraindication, to save the patient's life.
在大面积肺栓塞(PE)中,纤维蛋白溶解疗法是一种可能挽救生命的治疗方法;因此,如果没有其他可用的治疗方法,医生会面临这样一个问题:在存在绝对禁忌证的情况下,为了挽救患者的生命,我们能否接受纤维蛋白溶解疗法并发症的风险,尤其是颅内出血?在此,我们描述三例有纤维蛋白溶解疗法绝对禁忌证的大面积PE病例,这些患者因呼吸困难就诊于急诊科。由于无法进行外科或导管取栓术,且患者转至其他医院的风险非常高,因此给予了全身纤维蛋白溶解治疗。患者临床症状改善并出院。似乎,如果没有其他可接受的治疗方法,即使存在禁忌证,医生也可以考虑采用纤维蛋白溶解疗法来挽救患者的生命。